Clinical trial
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of…
NCT00116389 · Point Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00116389 |
|---|---|
| Title | Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas |
| Official title | An Open-Label Phase 2 Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas |
| Lead sponsor | Point Therapeutics, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma |
| Intervention type | Drug |
| Interventions | talabostat mesylate tablets, gemcitabine |
| Enrollment | 60 |
| First posted | Jun 29, 2005 |
| Last update posted | Jun 8, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: